Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every M&A move, funding round, exec hire, and contract on Viyash Lifesciences — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Viyash Lifesciences merges with SeQuent Scientific

PRIVATEFeb 07, 2026•3 months ago

Acquiring Company

Viyash Lifesciences

Acquired Company

SeQuent Scientific

MumbaiBiotechnologyHealth CareAnimal FeedPetVeterinary

Description

Viyash Lifesciences has merged with SeQuent Scientific, resulting in India's largest animal health company. The merger is valued at approximately ₹8,000 crore. This strategic move combines SeQuent’s animal health portfolio with Viyash’s human health APIs and formulations. The company anticipates significant benefits in R&D, manufacturing, and market positioning.

Company Information

Company

Viyash Lifesciences

About

Viyash Life Sciences specializes in the development and manufacturing of Active Pharmaceutical Ingredients (API). The company is known for its focus on high-quality products and innovative technologies in the pharmaceutical industry. Viyash works to create sustainable solutions that meet the evolving needs of their clients. They are positioned to strengthen the API supply chain within the health sector.

Predictive Intelligence
Strategic

ML-powered predictions for Viyash Lifesciences's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed